# US 11,079,393 B2 · Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,079,393 B2
- Document ID: US11079393B2
- Status: Granted
- Kind: B2
- Application number: 15/131,804
- Filed: 2016-04-18
- Published: 2016-10-06
- Granted: 2021-08-03
- Earliest claimed: 2010-10-25
- Assignees: Biogen MA Inc.
- Applicants: Biogen Ma Inc.
- Inventors: Alissa A. Chackerian
- Web page: https://patentgrep.com/patent/US11079393B2

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 16/2839: {against the integrin superfamily}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N 2333/70546: Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N 2333/7056: Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

## Claims

### Claim 1

A method of treating multiple sclerosis in an individual, comprising:
a) measuring a soluble molecule in a first biological sample obtained from the individual immediately before administration of a first dose of natalizumab, wherein the soluble molecule is sVCAM and/or sMAdCAM;
b) administering the first dose of natalizumab to the individual;
c) measuring the sVCAM and/or sMAdCAM in a second biological sample, wherein the second biological sample has been obtained from the individual within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days after administration of the first dose of natalizumab;
d) determining whether there is a decrease in the levels of the sVCAM and/or sMAdCAM between the first and second biological samples, wherein the decrease correlates with a decrease in alpha-4 integrin activity in the individual, and thereby determining whether there is a difference in alpha-4 integrin activity in the individual after administration of the first dose of natalizumab compared with before administration of the first dose of natalizumab; and
e) administering a second dose of natalizumab to the individual, wherein the second dose of the natalizumab is based on whether there is a decrease in the levels of the sVCAM and/or sMAdCAM between the first and second biological samples,
wherein:
the method comprises detecting no decrease or a statistically insignificant decrease (p>0.05) in the levels of sVCAM and/or sMAdCAM between the first and second biological samples, thereby determining that the first dose of the natalizumab is ineffective and the method further comprises adjusting the second dose of the natalizumab wherein the second dose is higher than the first dose.

### Claim 2 (depends on 1)

The method of claim 1, wherein alpha-4 integrin activity is alpha-4 beta-1 integrin activity, and wherein the soluble molecule is sVCAM.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first and/or the second biological sample is selected from the group consisting of a tissue, a cell, and a body fluid.

### Claim 4 (depends on 3)

The method of claim 3, wherein the first and/or the second biological sample is a body fluid selected from the group consisting of blood, sera, plasma, and cerebrospinal fluid.

### Claim 5 (depends on 3)

The method of claim 3, wherein the first and/or the second biological sample is in the form of frozen plasma or serum.

### Claim 6 (depends on 1)

The method of claim 1, wherein the second biological sample is obtained from the individual one day after administration of the first dose of the natalizumab.

### Claim 7 (depends on 1)

The method of claim 1, wherein the soluble molecule is measured by a method selected from the group consisting of enzyme-linked immunosorbent assays (ELISA), radioimmunoassay (RIA), Western blotting, and microbead-based protein detection assay.

### Claim 8

A method of treating multiple sclerosis in an individual, comprising:
a) measuring a soluble molecule in a first biological sample obtained from the individual immediately before administration of natalizumab, wherein the soluble molecule is sVCAM and/or sMAdCAM;
b) administering the first dose of the natalizumab to the individual;
c) measuring the sVCAM and/or sMAdCAM in a second biological sample, wherein the second biological sample has been obtained from the individual within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days after administration of the first dose of the natalizumab;
d) determining there is a decrease in the levels of the sVCAM and/or sMAdCAM between the first and second biological samples, wherein the decrease correlates with a decrease in alpha-4 integrin activity in the individual, and thereby determining whether there is a difference in alpha-4 integrin activity in the individual after administration of the first dose of natalizumab compared with before administration of the first dose of natalizumab; and
e) administering a second dose of natalizumab to the individual, wherein the second dose of natalizumab is calculated based on the decrease in the levels of the sVCAM and/or sMAdCAM between the first and second biological samples, wherein
the method comprises detecting a statistically significant decrease (p≤0.05) in the levels of sVCAM and/or sMAdCAM between the first and second biological samples, thereby determining that the first dose of natalizumab is effective and the method further comprises administering the second dose of natalizumab, wherein the second dose is the same as the first dose.

### Claim 9 (depends on 8)

The method of claim 8, wherein alpha-4 integrin activity is alpha-4 beta-1 integrin activity, and wherein the soluble molecule is sVCAM.

### Claim 10 (depends on 8)

The method of claim 8, wherein the first and/or the second biological sample is selected from the group consisting of a tissue, a cell, and a body fluid.

### Claim 11 (depends on 10)

The method of claim 10, wherein the first and/or the second biological sample is a body fluid selected from the group consisting of blood, sera, plasma, and cerebrospinal fluid.

### Claim 12 (depends on 10)

The method of claim 10, wherein the first and/or the second biological sample is in the form of frozen plasma or serum.

### Claim 13 (depends on 8)

The method of claim 8, wherein the second biological sample is obtained from the individual one day after administration of the first dose of the natalizumab.

### Claim 14 (depends on 8)

The method of claim 8, wherein the soluble molecule is measured by a method selected from the group consisting of enzyme-linked immunosorbent assays (ELISA), radioimmunoassay (RIA), Western blotting, and microbead-based protein detection assay.
